Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 9/20 | 0.48 |
| ▸ | CCR4 | P51679 | 4/20 | 0.36 |
| ▸ | CCKBR | P32239 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8110789 | 1.00 | FDFT1 (0.48) | FDFT1CCR4CCKBR | |
| SCHEMBL8110749 | 0.92 | FDFT1 (0.44) | FDFT1CCR4 | |
| SCHEMBL4110616 | 0.90 | FDFT1 (0.44) | FDFT1 | |
| SCHEMBL8102443 | 0.90 | FDFT1 (0.44) | FDFT1 | |
| SCHEMBL8116402 | 0.89 | FDFT1 (0.38) | FDFT1CCR4 | |
| SCHEMBL8116382 | 0.84 | FDFT1 (0.38) | FDFT1 | |
| SCHEMBL4112897 | 0.84 | FDFT1 (0.38) | FDFT1 | |
| SCHEMBL8112550 | 0.83 | FDFT1 (0.36) | FDFT1CCR4 | |
| SCHEMBL6957019 | 0.82 | FDFT1 (0.67) | FDFT1 | |
| SCHEMBL8636205 | 0.80 | FDFT1 (0.43) | FDFT1CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209510-A1 | Novel Method of Treating Hyperlipidemia | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-20 | — | — | US | disclosed |
| US-20090118255-A1 | Crp Lowering Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-07 | — | — | US | disclosed |
| US-20090082333-A1 | REMEDY FOR XANTHOMA | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20080132483-A1 | Agent for preventing or treating organ functional disorders and organ dysfunction | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-06-05 | — | — | US | disclosed |
| US-20080113965-A1 | Compound having inhibitory activity against squalene synthase or a salt or prodrug thereof, for example, N-[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid; myalgia or rhabdomyolysis treatment | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-15 | — | — | US | disclosed |
| US-20080058310-A1 | High-density lipoprotein-cholesterol level elevating agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-03-06 | — | — | US | disclosed |
| EP-1889632-A1 | REMEDY FOR XANTHOMA | National University Corp. Kobe University (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-20060241096-A1 | Agent for preventing or treating organ functional disorders and organ dysfunction | SUGIYAMA YASUO | 2006-10-26 | — | — | US | disclosed |
| US-20060052362-A1 | Skeletal muscle protecting agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-03-09 | — | — | US | disclosed |
| EP-1600166-A1 | SKELETAL MUSCLE PROTECTING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-11-30 | — | — | EP | disclosed |
| US-20040204500-A1 | Preventives/remedies for organ functional disorders and organ dysfunction | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-10-14 | — | — | US | disclosed |
| EP-1407782-A1 | PREVENTIVES/REMEDIES FOR ORGAN FUNCTIONAL DISORDERS AND ORGAN DYSFUNCTION | Takeda Chemical Industries, Ltd. (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-20040063750-A1 | High-density lipoprotein-cholesterol level elevating agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1332763-A1 | HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL LEVEL ELEVATING AGENT | Takeda Chemical Industries, Ltd. (JP) | 2003-08-06 | — | — | EP | disclosed |
| EP-0705607-A2 | Condensed seven- or eight-membered heterocyclic compounds useful as antihypertriglyceridemic agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082333-A1 | REMEDY FOR XANTHOMA | FDFT1, LSS, SQLE | FDFT1 1/4885CCR4 4835/4885CCKBR 3451/4885 |
| US-20080132483-A1 | Agent for preventing or treating organ functional disorders and organ dysfunction | FDFT1, SQOR, DHPS | FDFT1 1/4885CCR4 4769/4885CCKBR 3545/4885 |
| US-20040204500-A1 | Preventives/remedies for organ functional disorders and organ dysfunction | FDFT1, SQOR, DHPS | FDFT1 1/4885CCR4 4819/4885CCKBR 3758/4885 |
| US-20080058310-A1 | High-density lipoprotein-cholesterol level elevating agent | SREBF1, SREBF2, HDLBP | FDFT1 10/4885CCR4 4804/4885CCKBR 4508/4885 |
| US-20090118255-A1 | Crp Lowering Agent | SPR, RBP1, HMGCR | FDFT1 7/4885CCR4 1604/4885CCKBR 4112/4885 |
| US-20090209510-A1 | Novel Method of Treating Hyperlipidemia | HMGCR, LIPC, LIPA | FDFT1 12/4885CCR4 4846/4885CCKBR 3735/4885 |
| US-20080113965-A1 | Compound having inhibitory activity against squalene synthase or a salt or prodrug thereof, for example, N-[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid; myalgia or rhabdomyolysis treatment | SQLE, DHPS, COASY | FDFT1 13/4885CCR4 4856/4885CCKBR 4775/4885 |
| US-20060052362-A1 | Skeletal muscle protecting agent | GYS1, CPT1B, TNNC1 | FDFT1 8/4885CCR4 4818/4885CCKBR 4698/4885 |
| US-20060241096-A1 | Agent for preventing or treating organ functional disorders and organ dysfunction | FDFT1, SQOR, DHPS | FDFT1 1/4885CCR4 4769/4885CCKBR 3545/4885 |
| US-20040063750-A1 | High-density lipoprotein-cholesterol level elevating agent | SREBF1, SREBF2, HDLBP | FDFT1 10/4885CCR4 4804/4885CCKBR 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.